Maxillofacial Enlargement in Secondary Hyperparathyroidism Successfully Treated by Limited Parathyroidectomy and ParicalcitolMaxillofacial Enlargement in Secondary Hyperparathyroidism Successfully Treated by Limited Parathyroidectomy and Paricalcitol
- Other Titles
- Maxillofacial Enlargement in Secondary Hyperparathyroidism Successfully Treated by Limited Parathyroidectomy and Paricalcitol
- Authors
- Se Won Oh; Young Mo Lee; Jeong Yup Kim; Joo Kwang Wang; 고강지; 표희정; 서상일; 김성은; 이재복; 이지은; Seung Won Lee; 권영주
- Issue Date
- 2011
- Publisher
- 대한신장학회
- Keywords
- Renal osteodystrophy; Hyperparathyroidism; secondary; Maxillas
- Citation
- Kidney Research and Clinical Practice, v.30, no.6, pp.671 - 675
- Indexed
- KCI
- Journal Title
- Kidney Research and Clinical Practice
- Volume
- 30
- Number
- 6
- Start Page
- 671
- End Page
- 675
- URI
- https://scholar.korea.ac.kr/handle/2021.sw.korea/113797
- ISSN
- 2211-9132
- Abstract
- Maxillary enlargement is a rare complication of secondary hyperparathyroidism (SHPT). A 35-year-old Korean man undergoing chronic hemodialysis presented with a painless enlargement involving the maxilla and mandible. Plain radiography and CT scan showed bony expansion at the maxilla and mandible with multiple radiolucency. Serum intact parathyroid hormone (iPTH) was >1,600 pg/mL. Tc-99m sestamibi (MIBI) parathyroid scan and neck sonogram were compatible with SHPT. He underwent limited parathyroidectomy and commenced a course of paricalcitol. Fifteen months after surgery, maxillary enlargement and bony resorptions involving both hands markedly improved. Thirty-six months after the surgery, the serum iPTH level was 109.3 pg/mL. This is the first report in Korea documenting a patient with maxillary enlargement in SHPT who was successfully treated with limited parathyroidectomy and paricalcitol.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Medical Science > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.